Successful Treatment of Antifungal Combination Therapy with Inhaled Liposomal Amphotericin B and Oral Voriconazole for Intractable Chronic Progressive Pulmonary Aspergillosis

Overview

Journal Intern Med

Specialty General Medicine

Date 2021 Mar 8

PMID 33678738

Citations 2

Authors

Noboru Hamada

Mitsunori Ishiga

Suzuka Tanaka

Yasuhiro Ooue

Junko Itano

Hisaaki Tanaka

Shota Yuzurio

Takeshi Horiuchi

Toshimitsu Suwaki

Goro Kimura

Yasushi Tanimoto

Affiliations

Soon will be listed here.

Abstract

We experienced a case of the successful treatment of intractable pulmonary aspergillosis with inhaled liposomal amphotericin B (L-AMB) and oral voriconazole (VRCZ). A 52-year-old man was admitted to our hospital with a fever. Chest computed tomography (CT) revealed an infiltrative shadow. Two separate sputum cultures detected Aspergillus niger. Although we treated the patient with single and combined antifungal agents, the infiltrative shadow worsened. After obtaining sufficient informed consent from the patient, we switched him to an inhaled L-AMB. The infiltrative shadow subsequently improved. The patient has remained well for one year without exacerbation. We herein report the usefulness of inhaled L-AMB and oral VRCZ.

Citing Articles

Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges.

Tashiro M, Takazono T, Izumikawa K Ther Adv Infect Dis. 2024; 11:20499361241253751.

PMID: 38899061 PMC: 11186400. DOI: 10.1177/20499361241253751.

A Phase I/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis.

Fortun J, Gomez-Garcia de la Pedrosa E, Martinez-Lorca A, Paredes P, Martin-Davila P, Gomez-Lopez A J Fungi (Basel). 2024; 10(3).

PMID: 38535200 PMC: 10970827. DOI: 10.3390/jof10030191.

References

Araujo R, Rodrigues A . Variability of germinative potential among pathogenic species of Aspergillus. J Clin Microbiol. 2004; 42(9):4335-7. PMC: 516339. DOI: 10.1128/JCM.42.9.4335-4337.2004. View

Monforte V, Ussetti P, Gavalda J, Bravo C, Laporta R, Len O . Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant. 2010; 29(5):523-30. DOI: 10.1016/j.healun.2009.11.603. View

Moodley L, Pillay J, Dheda K . Aspergilloma and the surgeon. J Thorac Dis. 2014; 6(3):202-9. PMC: 3949189. DOI: 10.3978/j.issn.2072-1439.2013.12.40. View

Lee J, Lee C, Park I, Kim D, Chang J, Kim S . Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment. J Thorac Cardiovasc Surg. 2009; 138(4):820-5. DOI: 10.1016/j.jtcvs.2009.01.019. View

Dubois J, Bartter T, Gryn J, Pratter M . The physiologic effects of inhaled amphotericin B. Chest. 1995; 108(3):750-3. DOI: 10.1378/chest.108.3.750. View

Hanada S, Uruga H, Takaya H, Miyamoto A, Morokawa N, Kurosaki A . Nebulized liposomal amphotericin B for treating Aspergillus empyema with bronchopleural fistula. Am J Respir Crit Care Med. 2014; 189(5):607-8. DOI: 10.1164/rccm.201311-2086LE. View

Denning D, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S . Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2015; 47(1):45-68. DOI: 10.1183/13993003.00583-2015. View

Chong G, Broekman F, Polinder S, Doorduijn J, Lugtenburg P, Verbon A . Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life. Int J Antimicrob Agents. 2015; 46(1):82-7. DOI: 10.1016/j.ijantimicag.2015.02.023. View

Garcia M, Le Moal G, Cadranel J, Roblot F, Godet C . Efficacy of nebulized liposomal amphotericin B in the treatment of ABPA in an HIV/HBV co-infected man: Case report and literature review. J Asthma. 2018; 56(1):84-86. DOI: 10.1080/02770903.2018.1429467. View

10.

Sagawa M, Sakuma T, Isobe T, Sugita M, Waseda Y, Morinaga H . Cavernoscopic removal of a fungus ball for pulmonary complex aspergilloma. Ann Thorac Surg. 2004; 78(5):1846-8. DOI: 10.1016/j.athoracsur.2003.07.021. View

11.

Takeda K, Suzuki J, Watanabe A, Matsuki M, Higa K, Inoue E . Species identification, antifungal susceptibility, and clinical feature association of Aspergillus section Nigri isolates from the lower respiratory tract. Med Mycol. 2019; 58(3):310-314. DOI: 10.1093/mmy/myz072. View

12.

Caillot D, Thiebaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F . Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007; 110(12):2740-6. DOI: 10.1002/cncr.23109. View

13.

Kohno S, Tamura K, Niki Y, Izumikawa K, Oka S, Ogawa K . Executive Summary of Japanese Domestic Guidelines for Management of Deep-seated Mycosis 2014. Med Mycol J. 2016; 57(4):E117-E163. DOI: 10.3314/mmj.16-00010. View

14.

Giron J, Poey C, Fajadet P, Sans N, Fourcade D, Senac J . CT-guided percutaneous treatment of inoperable pulmonary aspergillomas: a study of 40 cases. Eur J Radiol. 1999; 28(3):235-42. DOI: 10.1016/s0720-048x(97)00148-4. View

15.

Purcell I, Corris P . Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Thorax. 1995; 50(12):1321-3. PMC: 1021361. DOI: 10.1136/thx.50.12.1321. View

16.

Gavalda J, Martin M, Lopez P, Gomis X, Ramirez J, Rodriguez D . Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother. 2005; 49(7):3028-30. PMC: 1168712. DOI: 10.1128/AAC.49.7.3028-3030.2005. View

17.

Panackal A, Parisini E, Proschan M . Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis. 2014; 28:80-94. PMC: 4237720. DOI: 10.1016/j.ijid.2014.07.007. View